Y-mabs Therapeutics (YMAB) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Y-mabs Therapeutics in October 2026.
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Y-mabs Therapeutics (YMAB) Stock Forecast
Analyst price target, next 12 months
$18.75
+120.3% vs today's $8.51
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Y-mabs Therapeutics have a consensus 12-month target of $18.75, above the current price of $8.51.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 14 Aug 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Y-mAbs stock, expecting its price could rise to $18.75.
Financial Health
Y-mAbs Therapeutics is performing well with strong revenue and profit margins, indicating healthy operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.